SGTX — Sigilon Therapeutics Share Price
0.000.00%
Last trade - 00:00- $56.50m
- $17.21m
- $12.94m
- 30
- 21
- 77
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.59 | ||
| Price to Tang. Book | 1.59 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.62 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -78.65% | ||
| Return on Equity | -75.76% | ||
| Operating Margin | -255.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.64 | 14.15 | 13.37 | 9.6 | 12.94 | 15.77 | 16 | 29.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sigilon Therapeutics, Inc. is a preclinical stage biotechnology company. The Company is focused on developing functional cures for patients with acute and chronic diseases by providing stable and durable levels of therapeutic molecules to patients. The Company’s Shielded Living Therapeutics (SLTx) platform is comprised of two primary elements: the cells and the sphere. The Company’s lead product candidate, SIG-002, is designed to replace islet cells for the treatment of Type 1 Diabetes (T1D). It is also developing product candidates for the treatment of lysosomal diseases. Its program for diabetes, it focused to apply the SLTx platform to develop product candidates, including product candidates for patients with liver and immune mediated diseases, and explore delivery of different molecules and alternative routes of administration. It also engineers cells to express a therapeutic molecule of choice in a continuous manner, which it refers to as constitutive expression.
Directors
- Rogerio Vivaldi Coelho PRE (56)
- Glenn Reicin CFO (56)
- May Orfali EVP
- Douglas Cole IND (60)
- John Cox IND (58)
- Stephen Oesterle IND (70)
- Kavita Patel IND (47)
- Robert Ruffolo IND (71)
- Eric Shaff IND (45)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- May 14th, 2015
- Public Since
- December 4th, 2020
- No. of Shareholders
- 26
- No. of Employees
- 62
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 2,501,908
- Address
- 100 Binney Street, Ste 600, CAMBRIDGE, 02142
- Web
- Phone
- +1 6173367540
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for SGTX
Q3 2023 Sigilon Therapeutics Inc Earnings Release
Similar to SGTX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Sigilon Therapeutics share price?
As of Today at 07:20 UTC, shares in Sigilon Therapeutics are trading at $21.20. This share price information is delayed by 15 minutes.
How has the Sigilon Therapeutics share price performed this year?
Shares in Sigilon Therapeutics last closed at $21.20 and the price had moved by +110.86% over the past 365 days. In terms of relative price strength the Sigilon Therapeutics share price has outperformed the S&P500 Index by +81.02% over the past year.
What are the analyst and broker recommendations for Sigilon Therapeutics?
The overall consensus recommendation for Sigilon Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Sigilon Therapeutics dividend yield?
Sigilon Therapeutics does not currently pay a dividend.
Does Sigilon Therapeutics pay a dividend?
Sigilon Therapeutics does not currently pay a dividend.
When does Sigilon Therapeutics next pay dividends?
Sigilon Therapeutics does not currently pay a dividend.
How do I buy Sigilon Therapeutics shares?
To buy shares in Sigilon Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sigilon Therapeutics?
As of the previous close price of $21.20, shares in Sigilon Therapeutics had a market capitalisation of $52.36m.
Where are Sigilon Therapeutics shares listed?
Here are the trading details for Sigilon Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SGTX
What kind of share is Sigilon Therapeutics?
Based on an overall assessment of its quality, value and momentum Sigilon Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sigilon Therapeutics share price forecast for 2023?
The analyst consensus target price for shares in Sigilon Therapeutics is $47.94. That is 126.13% above the last closing price of $21.20.
Analysts covering Sigilon Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$9.37 for the next financial year.
What is the trend in the Sigilon Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sigilon Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +107.62%.
As of the last closing price of $21.20, shares in Sigilon Therapeutics were trading +138.49% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sigilon Therapeutics PE Ratio?
The Sigilon Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $21.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sigilon Therapeutics?
Sigilon Therapeutics' management team is headed by:
- Rogerio Vivaldi Coelho - PRE
- Glenn Reicin - CFO
- May Orfali - EVP
- Douglas Cole - IND
- John Cox - IND
- Stephen Oesterle - IND
- Kavita Patel - IND
- Robert Ruffolo - IND
- Eric Shaff - IND